NGM Biopharmaceuticals

San Francisco, United States Founded: 2007 • Age: 19 yrs Listed
Biologics are developed for cardio-metabolic and liver diseases.

About NGM Biopharmaceuticals

NGM Biopharmaceuticals is a publicly listed company based in San Francisco (United States) founded in 2007 by Jin-Long Chen. Biologics are developed for cardio-metabolic and liver diseases. NGM Biopharmaceuticals has raised $358.87 million across 8 funding rounds from investors including Merck, The Column Group and Greenspring Associates. The company has 71 employees. NGM Biopharmaceuticals was last valued at $975 million in April 2019. Its chief executive, as recorded, is David J Woodhouse. NGM Biopharmaceuticals offers products and services including NGM120 and Pipeline Drugs. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Gastroenterology. Its legal entity is NGM Biopharmaceuticals, Inc. Its competitors include Rhythm Pharmaceuticals, MannKind Corp and Nimbus Therapeutics; 3 of its 3 listed competitors have raised funding.

Company details

NGM Biopharmaceuticals was founded in 2007 and is based in San Francisco, United States. Biologics are developed in the biopharmaceutical sector for treating cardio-metabolic and liver diseases. Operations focus on drug candidates such as NGM282, which targets bile acid-related conditions and non-alcoholic steatohepatitis. Additional candidates address Type 2 diabetes and obesity. Leadership is provided by CEO David J. Woodhouse.

  • Headquarters San Francisco, United States
  • Employees 71
  • Founders Jin-Long Chen
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Website ngmbio.com
  • Social LinkedIn X
  • Legal Name Ngm Biopharmaceuticals, Inc.
Key Metrics
  • Annual Revenue
    $330.53 M (USD)
    14.61
    as on Dec 31, 2025
  • Net Profit
    $22.2 M (USD)
    70.68
    as on Dec 31, 2025
  • EBITDA
    $39.07 M (USD)
    12.67
    as on Dec 31, 2025
  • Total Equity Funding
    $358.87M (USD)

    in 8 rounds

  • Latest Funding Round
    $142.04M (USD), Post-IPO

    Jul 2024

  • Investors
    Merck

    & 8 more

  • Employee Count
    71

Products & Services of NGM Biopharmaceuticals

NGM Biopharmaceuticals offers a comprehensive portfolio of products and services, including NGM120 and Pipeline Drugs.

NGM120
Biologic Drug

Drug candidate for treating Hyperemesis Gravidarum in clinical trials

Pipeline Drugs
Biologic Candidates

In-house developed drugs addressing various global diseases

Funding Insights of NGM Biopharmaceuticals

NGM Biopharmaceuticals has successfully raised a total of $358.87M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $142.04 million completed in July 2024. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $358.87M
  • Total Rounds 8
  • Last Round Post-IPO — $142.04M
  • First Round $25.5M

    (Feb 2008)

  • Investors Count 9

All 8 funding rounds of NGM Biopharmaceuticals with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Jul 2024$142.04MPost-IPO––
–
Mar 2015$106MSeries D–Merck
–
Feb 2015$57.5MSeries D–Prospect Venture Partners, TCG
Jul 2013$50MSeries C––
May 2013$13.49MSeries C––
–
Nov 2011$55.39MSeries C––
–
Mar 2010$51MSeries B––
Feb 2008$25.5MSeries A–Prospect Venture Partners, Rho Capital Partners
–
Valuation history

Last known valuation $975M (Apr 2019). 9 investors in total: 9 institutional.

Investors in NGM Biopharmaceuticals

NGM Biopharmaceuticals has secured backing from 9 investors, including venture fund and institutional investors. Prominent investors backing the company include Merck, The Column Group and Greenspring Associates.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Investments are made in US life sciences and healthtech firms.
prospectventures.comPalo Alto, United States
Early-stage investments in US life science startups are focused on.
2007thecolumngroup.comSan Francisco, United States
Topspin Consumer Partners is engaged in private equity investments focused on consumer brands.
topspincp.comMamaroneck, USA
Early-stage tech startups are invested in by Rho Capital Partners.
rho.comNew York, United States
Diversified investment management firm
2000greenspringassociates.comOwings Mills, United States
takedaventures.com
Multi-stage investment firm invests in healthcare and life sciences companies
foresitecapital.comNew York, United States
tichenorventures.com
Pharmaceutical products are manufactured and marketed worldwide.
1891merck.comKenilworth, United Kingdom
Premium access

Investor details for NGM Biopharmaceuticals

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

People of NGM Biopharmaceuticals

39 people are tracked at NGM Biopharmaceuticals (13 in leadership, 10 in board & advisors, 16 in team); the tracked headcount is 71.

NameRoleGroup
David J Woodhouse
CEOLeadership
Jin-Long Chen
FounderLeadership
Wendy Yeh
Chief Medical OfficerLeadership
Lulu Sterling
Senior Director, BiometricsLeadership
Vladimir Hanes
VP, Clinical Development OncologyLeadership
Diana Peng Bockus
Head of Business DevelopmentLeadership
Julie Roda
Director, Head Of Translational ScienceLeadership
Mahi Saraf
Associate Director, People & CultureLeadership
Fatima Larry
Director, Medical WritingLeadership
Kara Calhoun
Sr. Vice President, CMC & Process DevelopmentLeadership
Jean-Frederic Viret
Chief Financial Officer And Corporate Secretary (april 2024)Leadership
Scott Giese
Director, Downstream CMCLeadership
Ayako Kuroda
Associate Director, In Vivo ResourcesLeadership
Michael S. Brown
Chairman of Scientific Advisory BoardBoard & advisors
Grant Heidrich
Special AdvisorBoard & advisors
Roger M. Perlmutter
DirectorBoard & advisors
Michael Fischbach
Scientific Advisory Board MemberBoard & advisors
Robert D. Schreiber
Scientific Advisory Board MemberBoard & advisors
Joseph L. Goldstein
Scientific Advisory Board MemberBoard & advisors
Arthur D. Levinson
Special AdvisorBoard & advisors

19 more people are available in the full profile.

Premium access

Complete people profiles for NGM Biopharmaceuticals

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of NGM Biopharmaceuticals

NGM Biopharmaceuticals is a publicly listed company on the GETTEX with ticker symbol 0IK in Germany, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date05 Apr 2019
  • Listed onNASDAQ: NGM
  • Listed entityNGM Biopharmaceuticals, Inc.
  • Exchange sectorHealth technology
  • ISINGB00BS3DYQ52
  • Share price8.21 EUR (-2.15% on the day) · 2026-05-11
  • Market capitalisation1,560,000,000.00 EUR
  • Price to earnings54.7
  • Volume (last session)210
  • Analyst consensusNo rating

Financials of NGM Biopharmaceuticals

Exchange-reported annual figures
YearRevenueNet incomeEBITDA
2025281.3M EUR18.9M EUR33.2M EUR
2024245.4M EUR11.1M EUR29.5M EUR
2023246.6M EUR29.3M EUR40.6M EUR
2022172.3M EUR15.7M EUR22.5M EUR
2021121.6M EUR12.8M EUR19.7M EUR
Premium access

Detailed financial statements for NGM Biopharmaceuticals

Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.

  • Statement rows
  • Financial ratios
  • Five-year trends
  • Downloads

Verified entity values are shown only after access is granted.

Timeline of NGM Biopharmaceuticals

4 dated milestones of NGM Biopharmaceuticals across 17 years, from founding to its latest funding, stage changes and deals.

  1. Founded NGM Biopharmaceuticals is founded.
  2. Funding First funding round of $25.5M.
  3. IPO Lists on the stock exchange (IPO).
  4. Funding Latest funding round, Post-IPO, of $142.0M.

Competitors of NGM Biopharmaceuticals

NGM Biopharmaceuticals has 3 listed competitors in our database, 3 of them funded. They include Rhythm Pharmaceuticals, MannKind Corp and Nimbus Therapeutics.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
rhythmtx.com2010Boston, United States$84M115
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
mannkindcorp.com1991Los Angeles, United States$50M322
Developer of small-molecule drugs
nimbustx.com2009Cambridge, United States$685M81
Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed.
Premium access

Detailed competitors of NGM Biopharmaceuticals

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of NGM Biopharmaceuticals

The website of NGM Biopharmaceuticals (ngmbio.com) receives about 3.3K visits a month and ranks #4,587,249 among all websites worldwide, #5,487 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    3.3K

    ▼ 11.7% vs previous month

  • Unique visitors
    1.6K

    per month

  • Global rank
    #4,587,249

    among all websites

  • Category rank
    #5,487

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with NGM Biopharmaceuticals. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
novotech-cro.com
100%
49.2K#897,361View details
numerate.com
96%
View details
summitplc.com
summitplc.com
93%
–
bioseekinc.com
93%
View details
diabetesaustralia.com.au
57%
#282,620View details
••••••••••••••••.com••%•.•M#•••••–
••••••••••••••••.com••%•.•M#•••••–
Premium access

All 7 similar websites and full traffic analytics for NGM Biopharmaceuticals

The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.

  • 7 similar websites
  • Audience overlap
  • Engagement analytics
  • Traffic by brand

Verified entity values are shown only after access is granted.

Top companies in Metabolic Diseases

3 companies that operate in the same segment as NGM Biopharmaceuticals (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Satiety induction through digestable gastric balloon introduced via a swallowed capsule
2009Wellesley, Massachusetts, United StatesUSD 174.04 MUSD 32.11 M137
Developer of peptide therapeutics for the treatment of rare genetic deficiencies
2010Boston, Massachusetts, United StatesUSD 84 MUSD 189.76 M283
Developer of small-molecule drugs
1991Los Angeles, California, United StatesUSD 50 MUSD 348.97 M407
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Ngm Biopharmaceuticals

Premium access

Complete news archive for NGM Biopharmaceuticals

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about NGM Biopharmaceuticals

NGM Biopharmaceuticals was founded in 2007 and raised its 1st funding round 1 year after it was founded.

NGM Biopharmaceuticals is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.

David J Woodhouse is the CEO of NGM Biopharmaceuticals, as recorded in our data.

NGM Biopharmaceuticals is a funded company, having raised a total of $358.87M across 8 funding rounds to date. The company's 1st funding round was a Series A of $25.5M, raised on Feb 2008.

NGM Biopharmaceuticals has 71 employees.

Annual revenue of NGM Biopharmaceuticals is $330.53M as on Dec 31, 2025.

NGM Biopharmaceuticals was founded in 2007 and is based in San Francisco, United States. Biologics are developed in the biopharmaceutical sector for treating cardio-metabolic and liver diseases. Operations focus on drug candidates such as NGM282, which targets bile acid-related conditions and non-alcoholic steatohepatitis. Additional candidates address Type 2 diabetes and obesity. Leadership is provided by CEO David J. Woodhouse.

NGM Biopharmaceuticals's top competitors include Rhythm Pharmaceuticals, MannKind Corp and Nimbus Therapeutics.

NGM Biopharmaceuticals offers NGM120 and Pipeline Drugs.

Yes, NGM Biopharmaceuticals is publicly traded on GETTEX under the ticker symbol 0IK.

NGM Biopharmaceuticals has 9 investors. Key investors include Merck, The Column Group, Greenspring Associates, Prospect Venture Partners, and Topspin Consumer Partners.

The valuation of NGM Biopharmaceuticals is $975M as of Apr 2019.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available